Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$25.48
At close: Apr 7, 7:49 PM EDT
$25.50
0.020.08%
After Hours: 7:49 PM EDT
Comments
Loading...
Avidity Biosciences Analyst Ratings and Price Targets | NASDAQ:RNA | Benzinga
Avidity Biosciences Inc has a consensus price target of $60.44 based on the ratings of 18 analysts. The high is $96 issued by Cantor Fitzgerald on September 18, 2024. The low is $20 issued by Evercore ISI Group on March 31, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Needham, and HC Wainwright & Co. on March 18, 2025, March 17, 2025, and March 17, 2025, respectively. With an average price target of $68 between HC Wainwright & Co., Needham, and HC Wainwright & Co., there's an implied 166.67% upside for Avidity Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
Chardan Capital
Citigroup
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Avidity Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 182.35% | HC Wainwright & Co. | Andrew Fein54% | $72 → $72 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 135.29% | Needham | Joseph Stringer47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 182.35% | HC Wainwright & Co. | Andrew Fein54% | $72 → $72 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 154.9% | Chardan Capital | Keay Nakae55% | $65 → $65 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 174.51% | Citigroup | Geoff Meacham61% | → $70 | Initiates | → Buy | Get Alert |
| 03/12/2025 | Buy Now | 182.35% | BMO Capital | Kostas Biliouris32% | → $72 | Initiates | → Outperform | Get Alert |
| 03/10/2025 | Buy Now | 88.24% | B of A Securities | Geoff Meacham61% | $51 → $48 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | 174.51% | Scotiabank | Louise Chen54% | → $70 | Initiates | → Sector Outperform | Get Alert |
| 02/28/2025 | Buy Now | 123.53% | Barclays | Gena Wang50% | $63 → $57 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 154.9% | Chardan Capital | Keay Nakae55% | $65 → $65 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | 162.75% | RBC Capital | Luca Issi38% | $67 → $67 | Reiterates | Outperform → Outperform | Get Alert |
| 01/10/2025 | Buy Now | 182.35% | HC Wainwright & Co. | Andrew Fein54% | $72 → $72 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 182.35% | HC Wainwright & Co. | Andrew Fein54% | → $72 | Initiates | → Buy | Get Alert |
| 11/26/2024 | Buy Now | 162.75% | RBC Capital | Luca Issi38% | → $67 | Initiates | → Outperform | Get Alert |
| 11/13/2024 | Buy Now | 154.9% | Chardan Capital | Keay Nakae55% | $65 → $65 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 135.29% | Needham | Joseph Stringer47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 135.29% | Needham | Joseph Stringer47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2024 | Buy Now | 154.9% | Chardan Capital | Keay Nakae55% | $60 → $65 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | 205.88% | TD Cowen | Ritu Baral35% | $56 → $78 | Maintains | Buy | Get Alert |
| 09/24/2024 | Buy Now | 131.37% | Goldman Sachs | Corinne Johnson21% | → $59 | Initiates | → Buy | Get Alert |
| 09/18/2024 | Buy Now | 276.47% | Cantor Fitzgerald | Eric Schmidt28% | $96 → $96 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 276.47% | Cantor Fitzgerald | Eric Schmidt28% | $96 → $96 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 276.47% | Cantor Fitzgerald | Eric Schmidt28% | $96 → $96 | Reiterates | Overweight → Overweight | Get Alert |
| 08/28/2024 | Buy Now | 147.06% | Barclays | Gena Wang50% | → $63 | Initiates | → Overweight | Get Alert |
| 08/26/2024 | Buy Now | 107.84% | Evercore ISI Group | Josh Schimmer52% | $54 → $53 | Maintains | Outperform | Get Alert |
| 08/13/2024 | Buy Now | 135.29% | Needham | Joseph Stringer47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 111.76% | Evercore ISI Group | Josh Schimmer52% | $45 → $54 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | 135.29% | Chardan Capital | Keay Nakae55% | $45 → $60 | Maintains | Buy | Get Alert |
| 06/13/2024 | Buy Now | 76.47% | B of A Securities | Geoff Meacham61% | $40 → $45 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | 80.39% | Needham | Joseph Stringer47% | $35 → $46 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | 76.47% | Chardan Capital | Keay Nakae55% | $33 → $45 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | 76.47% | Evercore ISI Group | Josh Schimmer52% | $40 → $45 | Maintains | Outperform | Get Alert |
| 06/10/2024 | Buy Now | 37.25% | Needham | Joseph Stringer47% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 37.25% | Needham | Joseph Stringer47% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 29.41% | Chardan Capital | Keay Nakae55% | $33 → $33 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 56.86% | B of A Securities | Geoff Meacham61% | → $40 | Initiates | → Buy | Get Alert |
| 04/11/2024 | Buy Now | 37.25% | Needham | Joseph Stringer47% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 135.29% | Cantor Fitzgerald | Eric Schmidt28% | → $60 | Initiates | → Overweight | Get Alert |
| 03/05/2024 | Buy Now | 29.41% | Chardan Capital | Keay Nakae55% | $23 → $33 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 37.25% | Needham | Joseph Stringer47% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 37.25% | Needham | Joseph Stringer47% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | -9.8% | Chardan Capital | Keay Nakae55% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | Buy Now | 96.08% | Wells Fargo | Yanan Zhu35% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/29/2023 | Buy Now | 37.25% | Needham | Joseph Stringer47% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 17.65% | Credit Suisse | Judah Frommer66% | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | -9.8% | Chardan Capital | Keay Nakae55% | $27 → $23 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | 37.25% | Needham | Joseph Stringer47% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | -21.57% | Evercore ISI Group | Josh Schimmer52% | → $20 | Upgrade | In-Line → Outperform | Get Alert |
| 05/17/2023 | Buy Now | 37.25% | Needham | Joseph Stringer47% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 96.08% | Wells Fargo | Yanan Zhu35% | $55 → $50 | Maintains | Overweight | Get Alert |
| 05/10/2023 | Buy Now | 17.65% | Credit Suisse | Judah Frommer66% | → $30 | Reiterates | → Outperform | Get Alert |
| 04/28/2023 | Buy Now | 37.25% | Needham | Joseph Stringer47% | → $35 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | 17.65% | Credit Suisse | Judah Frommer66% | $35 → $30 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | -21.57% | Evercore ISI Group | Joshua Schimmer44% | → $20 | Downgrade | Outperform → In-Line | Get Alert |
| 03/31/2023 | Buy Now | 5.88% | Chardan Capital | Keay Nakae55% | → $27 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 37.25% | Credit Suisse | Judah Frommer66% | → $35 | Reiterates | → Outperform | Get Alert |
| 03/01/2023 | Buy Now | 5.88% | Chardan Capital | Keay Nakae55% | → $27 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 37.25% | Needham | Joseph Stringer47% | → $35 | Reiterates | → Buy | Get Alert |
| 01/04/2023 | Buy Now | 115.69% | Wells Fargo | Yanan Zhu35% | $60 → $55 | Maintains | Overweight | Get Alert |
| 12/15/2022 | Buy Now | 37.25% | Credit Suisse | Judah Frommer66% | $33 → $35 | Maintains | Outperform | Get Alert |
| 12/15/2022 | Buy Now | 178.43% | Raymond James | Steven Seedhouse58% | $30 → $71 | Maintains | Strong Buy | Get Alert |
| 12/14/2022 | Buy Now | 178.43% | Raymond James | Steven Seedhouse58% | $30 → $71 | Maintains | Strong Buy | Get Alert |
| 11/09/2022 | Buy Now | 29.41% | Credit Suisse | Judah Frommer66% | $32 → $33 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 17.65% | Raymond James | Steven Seedhouse58% | $29 → $30 | Maintains | Strong Buy | Get Alert |
| 09/27/2022 | Buy Now | 37.25% | Needham | Joseph Stringer47% | $50 → $35 | Maintains | Buy | Get Alert |
| 09/27/2022 | Buy Now | 5.88% | Chardan Capital | Keay Nakae55% | $29 → $27 | Maintains | Buy | Get Alert |
| 07/20/2022 | Buy Now | 13.73% | Chardan Capital | Keay Nakae55% | → $29 | Initiates | → Buy | Get Alert |
| 07/12/2022 | Buy Now | 13.73% | Raymond James | Steven Seedhouse58% | → $29 | Initiates | → Strong Buy | Get Alert |
| 05/11/2022 | Buy Now | 25.49% | Credit Suisse | Judah Frommer66% | $36 → $32 | Maintains | Outperform | Get Alert |
| 05/11/2022 | Buy Now | 96.08% | SVB Leerink | Joseph Schwartz65% | $53 → $50 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Avidity Biosciences (RNA) stock?
The latest price target for Avidity Biosciences (NASDAQ:RNA) was reported by HC Wainwright & Co. on March 18, 2025. The analyst firm set a price target for $72.00 expecting RNA to rise to within 12 months (a possible 182.35% upside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avidity Biosciences (RNA)?
The latest analyst rating for Avidity Biosciences (NASDAQ:RNA) was provided by HC Wainwright & Co., and Avidity Biosciences reiterated their buy rating.
When was the last upgrade for Avidity Biosciences (RNA)?
The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.
When was the last downgrade for Avidity Biosciences (RNA)?
The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.
When is the next analyst rating going to be posted or updated for Avidity Biosciences (RNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating Avidity Biosciences (RNA) correct?
While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a reiterated with a price target of $72.00 to $72.00. The current price Avidity Biosciences (RNA) is trading at is $25.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.